Skip to main content
. Author manuscript; available in PMC: 2022 Sep 9.
Published in final edited form as: Acta Ophthalmol. 2021 Mar 19;100(1):e91–e99. doi: 10.1111/aos.14852

Table 4.

Paediatric development: deafness, blindness, walking ability and cerebral palsy at year 2.

Ranibizumab 0.12 mg (N = 8) Ranibizumab 0.20 mg (N = 7) Total (N = 15)
Deafness present No deafness [N, infants (%)] 8 (100) 7 (100) 15 (100)
Infant wearing hearing aids Not present [N, infants (%)] 8 (100) 7 (100) 15 (100)
Blindness present No blindness [N, infants (%)] 8 (100) 6 (86) 14 (93)
In both eyes [N, infants (%)] - 1 (14) 1 (7)
Infant wearing Yes [N, infants (%)] 1 (13) - 1 (7)
 glasses No [N, infants (%)] 7 (88) 7 (100) 14 (93)
Infant able to walk Yes [N, infants (%)] 7 (88) 4 (57)* 11 (73)
No [N, infants (%)] 1 (13) 3 (43) 4 (27)
Cerebral palsy present No cerebral palsy [N, infants (%)] 8 (100) 7 (100) 15 (100)
*

One child able to walk with walking aid.